Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PTGX – Protagonist Therapeutics Inc

PTGX — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

13.44

Margin Of Safety %

-32

Put/Call OI Ratio

0.41

EPS Next Q Diff

2.1

EPS Last/This Y

4.82

EPS This/Next Y

-3.21

Price

103.75

Target Price

112.69

Analyst Recom

1.23

Performance Q

23.25

Upside

-125.6%

Beta

2.12

Ticker: PTGX




16 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-09PTGX97.460.090.146496
2026-03-10PTGX97.140.090.076460
2026-03-11PTGX96.50.095.356464
2026-03-12PTGX95.530.130.226732
2026-03-13PTGX95.420.130.226732
2026-03-17PTGX97.280.140.706860
2026-03-18PTGX97.110.160.267450
2026-03-20PTGX98.940.240.077646
2026-03-25PTGX104.360.180.116232
2026-03-26PTGX102.050.184.216246
2026-03-27PTGX99.730.201.306328
2026-03-30PTGX99.880.210.066399
2026-03-31PTGX104.60.210.146432
2026-04-01PTGX103.740.220.036376
2026-04-06PTGX102.940.410.007379
2026-04-07PTGX103.660.410.007360
DateSymbolLatestP/C OIP/C VolTotal OI
16 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-09PTGX96.72-202.4- 2.75
2026-03-10PTGX97.10-202.4- 2.75
2026-03-11PTGX96.48-202.4- 2.75
2026-03-12PTGX95.45-202.4- 2.75
2026-03-13PTGX92.37-202.4- 2.75
2026-03-17PTGX97.24-202.4- 2.75
2026-03-18PTGX97.14-202.4- 2.75
2026-03-19PTGX101.67-202.4- 2.75
2026-03-20PTGX98.90-202.4- 2.75
2026-03-23PTGX98.47-202.4- 2.75
2026-03-24PTGX100.39-244.3- 2.77
2026-03-25PTGX104.19-244.3- 2.77
2026-03-26PTGX102.06-244.3- 2.77
2026-03-27PTGX98.84-244.3- 2.77
2026-03-30PTGX99.81-244.3- 2.77
2026-03-31PTGX105.49-244.3- 2.77
2026-04-01PTGX103.68-244.3- 2.77
2026-04-02PTGX103.72-244.3- 2.77
2026-04-06PTGX102.96-244.3- 2.77
2026-04-07PTGX103.75-244.3- 2.77
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-09PTGX-5.601.9614.08
2026-03-10PTGX-5.601.9614.08
2026-03-11PTGX-5.601.9613.66
2026-03-12PTGX-5.601.9613.66
2026-03-13PTGX-5.601.9613.66
2026-03-18PTGX-5.602.0013.66
2026-03-19PTGX-5.602.0013.66
2026-03-20PTGX-5.602.0013.66
2026-03-23PTGX-5.602.0013.66
2026-03-24PTGX-5.602.0013.66
2026-03-25PTGX-5.512.0013.44
2026-03-26PTGX-6.772.0013.44
2026-03-27PTGX-6.772.0013.44
2026-03-30PTGX-8.202.0213.44
2026-03-31PTGX-8.202.0213.44
2026-04-01PTGX-8.202.0213.44
2026-04-02PTGX-8.202.0213.44
2026-04-06PTGX-8.202.0213.44
2026-04-07PTGX-8.202.0213.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.69

Avg. EPS Est. Current Quarter

-0.65

Avg. EPS Est. Next Quarter

1.41

Insider Transactions

-8.2

Institutional Transactions

2.02

Beta

2.12

Average Sales Estimate Current Quarter

16

Average Sales Estimate Next Quarter

143

Fair Value

70.27

Quality Score

24

Growth Score

32

Sentiment Score

98

Actual DrawDown %

3.8

Max Drawdown 5-Year %

-85.8

Target Price

112.69

P/E

Forward P/E

PEG

P/S

143.85

P/B

10.56

P/Free Cash Flow

118.05

EPS

-2.04

Average EPS Est. Cur. Y​

2.77

EPS Next Y. (Est.)

-0.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-282.83

Relative Volume

0.97

Return on Equity vs Sector %

-48.6

Return on Equity vs Industry %

-32.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.03

EBIT Estimation

PTGX Healthcare
$103.75
📉
Swing / Pullback
Buy the dip on strong trends
32 /100
WEAK
Trend
0/20
Pullback
10/25
Volume
7/15
Valuation
4/20
TP/AR
4/10
Options
7/10
RSI
61.4
Range 1M
72.1%
Sup Dist
2%
🚀
Momentum Growth
Ride accelerating trends
N/A
36 /100
WEAK
Momentum
6/25
Growth
12/30
Estimates
2/20
Inst/Vol
9/15
Options
7/10
EPS Yr
257.6%
EPS NY
-120.9%
52W%
92.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🔴 SELL -15.9% upside
Quality
6/30
Valuation
1/30
Growth
7/25
Stability
8/10
LT Trend
1/5
Upside
-15.9%
Quality
24
MoS
-32%
Protagonist Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 132
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX

Latest News

Caricamento notizie per PTGX
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading